V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230001371 | 230000978 | 1.77 | 84 | Adjuvant (A) | 2014-11-13 | 2014-11-20 | Capecitabine | N | N | 230017769 | CISPLATIN + GEMCITABINE |
| 230001372 | 230000979 | 1.85 | null | Adjuvant (A) | 2015-04-21 | 2015-05-20 | Carboplatin + Etoposide iv&po | N | null | 230018036 | PEMBROLIZUMAB |
| 230001373 | 230000980 | 1.62 | 122 | Neo-adjuvant (N) | 2016-08-25 | 2016-08-26 | Capecitabine | 02 | N | 230018064 | FEC |
| 230001374 | 230000981 | 1.8 | 76.8 | Palliative (P) | 2015-12-05 | 2015-12-10 | LENVATINIB | 2 | N | 230018214 | CARBOPLATIN + ETOPOSIDE |
| 230001375 | 230000982 | 1.66 | 70.1 | Palliative (P) | 2017-11-25 | 2017-12-16 | Bevacizumab + Capecitabine | 2 | N | 230018373 | IRINOTECAN + MDG |
| 230001376 | 230000982 | null | 70.3 | Adjuvant (A) | 2018-06-20 | 2018-07-05 | LEAM | N | N | 230018373 | TRASTUZUMAB |
| 230001377 | 230000983 | 1.62 | null | Neo-adjuvant (N) | 2018-06-25 | 2018-07-27 | Irinotecan + Modified De Gramont | 02 | null | 230019072 | CISPLATIN + GEMCITABINE |
| 230001378 | 230000984 | 1.74 | 69.3 | Palliative (P) | 2015-09-29 | 2015-11-11 | Bevacizumab 5mg/kg | 02 | N | 230019072 | BEVACIZUMAB |
| 230001379 | 230000985 | 1.58 | null | Not known (9) | 2016-06-19 | 2016-09-01 | Ipilimumab | 02 | N | 230019683 | ESPAC TRIAL |
| 230001380 | 230001417 | 1.53 | 69.8 | Curative (C) | 2016-03-16 | 2016-03-22 | Capecitabine + Oxaliplatin 21day | N | N | 230020135 | CAPECITABINE + OXALIPLATIN |
| 230001381 | 230000987 | 0 | 77 | Curative (C) | 2016-09-26 | 2016-10-14 | Sorafenib | N | N | 230020193 | CISPLATIN + ETOPOSIDE |
| 230001382 | 230000988 | 0 | 46.7 | Adjuvant (A) | 2018-09-16 | 2018-10-10 | Docetaxel 100mg/m2 (21 day) | 2 | N | 230020455 | CARBOPLATIN + ETOPOSIDE |
| 230001383 | 230000988 | 1.7 | null | Adjuvant (A) | 2017-08-05 | 2017-08-09 | Mitomycin Intravesical | 02 | N | 230020455 | FLUOROURACIL + MITOMYCIN + RT |
| 230001384 | 230000990 | null | 69.6 | Not known (9) | 2017-03-14 | 2017-03-28 | FLUOROURACIL + IRINOTECAN | 2 | N | 230021625 | ENZALUTAMIDE |
| 230001385 | 230000991 | 1.55 | 73.7 | Not known (9) | 2019-03-10 | 2019-04-01 | Docetaxel + Trastuzumab (Maint) | N | Y | 230021656 | TRABECTEDIN |
| 230001386 | 230000992 | 1.85 | 96.5 | Adjuvant (A) | 2015-08-21 | 2015-09-30 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | 230021656 | CAPECITABINE + OXALIPLATIN |
| 230001387 | 230000994 | 1.6 | 50.6 | Curative (C) | 2016-03-06 | 2016-03-16 | FEC + TRASTUZUMAB | 02 | N | 230021849 | METHOTREXATE INTRATHECAL |
| 230001388 | 230001421 | 1.65 | 122 | Palliative (P) | 2019-05-27 | 2019-06-23 | CTD | 02 | N | 230021984 | CAPECITABINE + OXALIPLATIN |
| 230001389 | 230000995 | 1.69 | 53.7 | Curative (C) | 2016-02-12 | 2016-02-14 | PACLITAXEL | N | N | 230022554 | OXALIPLATIN + MDG |
| 230001390 | 230000996 | 1.85 | 99 | Adjuvant (A) | null | 2013-04-12 | Capecitabine | N | N | 230022558 | TRASTUZUMAB |
| 230001391 | 230000997 | 1.82 | 72.05 | Curative (C) | null | 2014-03-16 | Capecitabine + Oxaliplatin 14day | 2 | N | 230023120 | GEMCITABINE |
| 230001392 | 230000998 | 1.7 | 69 | Neo-adjuvant (N) | 2016-07-24 | 2016-08-18 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | 230023262 | FLUOROURACIL + MITOMYCIN + RT |
| 230001393 | 230000998 | 1.57 | 59.7 | Palliative (P) | 2015-08-03 | 2015-08-03 | CAPECITABINE + OXALIPLATIN | null | N | 230023262 | TRASTUZUMAB |
| 230001394 | 230000999 | 1.68 | 43.2 | Curative (C) | 2018-03-21 | 2018-03-28 | FEC + TRASTUZUMAB | null | N | 230023380 | IPILIMUMAB |
| 230001395 | 230001004 | 1.7 | null | Palliative (P) | 2017-09-16 | 2018-06-20 | CAPECITABINE + OXALIPLATIN | 2 | N | 230023710 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 230001396 | 230001005 | null | null | Curative (C) | 2013-12-27 | 2013-12-29 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 230024026 | CAPECITABINE + OXALIPLATIN |
| 230001397 | 230001007 | 1.49 | 74.8 | Palliative (P) | 2016-10-19 | 2016-11-14 | PEMBROLIZUMAB | N | N | 230024332 | DOCETAXEL + TRASTUZUMAB |
| 230001398 | 230001009 | 1.77 | 82.8 | Palliative (P) | 2016-10-21 | 2016-10-22 | Oxaliplatin + Modified de Gramont | N | N | 230024684 | CISPLATIN + GEMCITABINE |
| 230001399 | 230001009 | 1.75 | 92.65 | Palliative (P) | 2017-09-04 | 2017-09-09 | Trifluridine + Tipiracil | 02 | N | 230024684 | TRASTUZUMAB |
| 230001400 | 230001010 | null | 68.4 | Not known (9) | 2016-10-22 | 2016-10-22 | Docetaxel 100mg/m2 (21 day) | N | null | 230025230 | GEMCITABINE |
| 230001401 | 230001011 | 1.58 | 82.5 | Neo-adjuvant (N) | 2018-01-24 | 2018-01-24 | Capecitabine + Oxaliplatin 21day | N | N | 230025230 | FEC |
| 230001402 | 230001015 | null | 110.1 | Palliative (P) | 2017-05-27 | 2017-07-09 | CETUXIMAB | N | N | 230025405 | CISPLATIN + RT |
| 230001403 | 230001018 | 1.68 | 71 | null | 2015-10-31 | 2015-11-12 | Capecitabine + Oxaliplatin 21day | N | N | 230025600 | CISPLATIN + PEMETREXED |
| 230001404 | 230001019 | 1.7 | null | Adjuvant (A) | 2015-05-14 | 2015-05-15 | Rituximab | 2 | Y | 230025893 | CAPECITABINE + OXALIPLATIN |
| 230001405 | 230001021 | 1.68 | 65.3 | Adjuvant (A) | 2017-11-25 | 2017-11-28 | Trastuzumab Subcutaneous | N | N | 230026253 | IRINOTECAN + MDG |
| 230001406 | 230001021 | 1.76 | 95.1 | Adjuvant (A) | 2015-12-18 | 2016-04-07 | FLUOROURACIL + IRINOTECAN | 02 | Y | 230026253 | TRASTUZUMAB |
| 230001407 | 230001619 | 1.67 | 74.8 | Curative (C) | 2016-06-06 | 2016-06-06 | FEC 100 + DOCETAXEL | N | N | 230026563 | TRASTUZUMAB |
| 230001408 | 230001619 | 1.59 | 69 | Adjuvant (A) | 2016-11-26 | 2016-11-27 | TRASTUZUMAB | 02 | Y | 230026563 | TRASTUZUMAB |
| 230001409 | 230001022 | 1.79 | 70.5 | Curative (C) | 2016-10-07 | 2016-10-07 | CVP R | N | N | 230026820 | CISPLATIN + GEMCITABINE |
| 230001410 | 230001022 | 1.68 | 50.6 | Palliative (P) | 2015-10-04 | 2015-10-04 | ESPAC-4 TRIAL | 2 | null | 230026820 | BENDAMUSTINE + RITUXIMAB |
| 230001411 | 230001027 | null | 50.6 | Adjuvant (A) | 2017-04-17 | 2017-10-29 | FLUOROURACIL + OXALIPLATIN | N | null | 230027620 | FEC |
| 230001412 | 230001028 | 1.86 | 74 | Palliative (P) | 2017-04-09 | 2017-04-21 | Oxaliplatin + Modified de Gramont | 02 | N | 230028415 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 230001413 | 230001030 | 1.86 | 91.7 | Curative (C) | 2018-03-26 | 2018-04-10 | Capecitabine + Oxaliplatin 21day | N | N | 230028464 | GEMCITABINE |
| 230001414 | 230001430 | 1.7 | 79.9 | Adjuvant (A) | 2017-08-03 | 2018-05-04 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | 230028488 | ESPAC TRIAL |
| 230001415 | 230001620 | null | null | null | null | 2017-08-30 | Docetaxel 75mg/m2 (21 day) | 2 | N | 230001447 | AXITINIB |
| 230001416 | 230001032 | 1.6 | 69 | null | 2014-09-15 | 2014-09-25 | CARBOPLATIN + RT | N | null | 230001770 | RITUXIMAB |
| 230001417 | 230001433 | 1.57 | 95.4 | Neo-adjuvant (N) | 2017-12-14 | 2017-12-29 | Trastuzumab Subcutaneous | N | N | 230001793 | FLUOROURACIL + MITOMYCIN + RT |
| 230001418 | 230001033 | 1.79 | 92.1 | null | 2016-04-26 | 2016-04-27 | Cetuximab + Oxaliplatin + MdG Load | N | null | 230002211 | HYDROXYCARBAMIDE |
| 230001419 | 230001034 | 1.53 | null | Not known (9) | 2010-05-26 | 2015-03-26 | FLUOROURACIL + MITOMYCIN + RT | N | N | 230002253 | ETOPOSIDE |
| 230001420 | 230001035 | 1.65 | 0 | Adjuvant (A) | 2018-11-03 | 2018-11-06 | Sorafenib | 2 | N | 230003804 | CAPECITABINE + OXALIPLATIN |